liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
Antoni Van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, Netherlands, Slotervaart Hospital, Amsterdam, Netherlands.
Antoni Van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, Netherlands, Slotervaart Hospital, Amsterdam, Netherlands, Dept. of Pharmacy and Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, Netherlands.
Petrov Res. Institute of Oncology, St-Petersburg, Russian Federation.
Onkologiska Kliniken, Uppsala, Sweden.
Show others and affiliations
2004 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 91, no 8, 1434-1441 p.Article in journal (Refereed) Published
Abstract [en]

The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n = 41), 350 mg m-2 irinotecan as a 90-min i.v. infusion q3 weeks, arm B (n = 38), 125 mg m-2 irinotecan as a 90-min i.v. infusion weekly x 4 weeks q6 weeks, arm C (n = 46), 250 mg m-2 irinotecan as a 90-min i.v. infusion q2 weeks, or arm D (n = 49), 10 mg m -2 day-1 irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months, P = 0.02). Overall response rates were in the range 5-11%. Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months). Similarly, there were no significant differences in the incidence of grade 3-4 toxicities, although the toxicity profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic syndrome were observed in arm D, however, there was a trend for increased gastrointestinal toxicity. Irinotecan is an effective and safe second-line treatment for colorectal cancer. The schedules examined yielded equivalent results, indicating that there is no advantage of the prolonged vs short infusion schedules. © 2004 Cancer Research UK.

Place, publisher, year, edition, pages
2004. Vol. 91, no 8, 1434-1441 p.
Keyword [en]
Colorectal cancer, CPT-11, Efficacy, Irinotecan, Pharmacokinetics, Safety
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:liu:diva-45601DOI: 10.1038/sj.bjc.6602172OAI: oai:DiVA.org:liu-45601DiVA: diva2:266497
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13

Open Access in DiVA

No full text

Other links

Publisher's full text
In the same journal
British Journal of Cancer
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf